This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
The sources searched to identify primary studies were not stated.
Criteria used to ensure the validity of primary studies
The criteria used to ensure the validity of primary sources were not stated.
Methods used to judge relevance and validity, and for extracting data
The methods used to judge relevance, validity when extracting data were not stated.
Number of primary studies included
In excess of 70 primary studies were considered in determining the effectiveness evidence. These are reported in detail in Table 1 in the original paper.
Methods of combining primary studies
A narrative method was employed. The authors chose values near to the average of the reported range.
Investigation of differences between primary studies
An investigation of differences between primary studies was not made.
Results of the review
Disease progression results showed that the mean time from initial infection to AIDS for both non-injection drug users and injection drug users not in MMT was 11.5 years. For injection drug users in MMT this was 12.2 years. The mean time from AIDS to death for all individuals was 2.6 years.
The probability of HIV transmission per sexual partner with HIV (not AIDS) was 0.05, and with AIDS was 0.11.
Probability of HIV transmission per risky needle injection was 0.005 (sensitivity analysis was performed between values of 0.001 and 0.01).
The full list of parameters and values is presented in Table 1 of the original paper, whilst the list of sensitivity analysis maximum and minimum values is in Table 3 .
All health care costs were considered, whether for HIV care or non-HIV care, as well as the cost for methadone maintenance. The cost of MMT was derived from a study of 600 MMT programmes. Full details of the cost calculations are provided in another paper by the same authors (in press at the time of writing). The health care costs were derived from sources between 1994 and 1998and were given in 1998US dollars after adjusting for inflation. Direct costs were discounted at 3% since the time horizon was 10 years. Quantities and costs were reported separately. It was assumed that the extra MMT programmes were as costly as the existing ones.
Indirect Costs
No indirect costs were considered in the model.
Currency

US dollars ($).
Sensitivity analysis
Univariate sensitivity analysis was performed on key parameters, and those parameters for which estimations and assumptions had been used. These included death rates, treatment completion, sexual behaviour, drug injection behaviour, HIV transmission rates, QALY values for health states and costs. A full summary of the sensitivity analysis is provided in Table 3 of the paper.
Estimated benefits used in the economic analysis
In the high prevalence community, the 10% expansion of MMT programmes resulted in 264 (discounted) averted HIV infections (reducing HIV prevalence by 0.022%). This resulted in a gain of 1,300 QALYs over the 10 year period (discounted). In the low prevalence community, the 10% expansion of MMT programmes resulted in 34 (discounted) averted HIV infections (reducing HIV prevalence by 0.003%). This resulted in a gain of 301 QALYs over the 10 year period (discounted). No side-effects were considered in the analysis.
Cost results
For the high prevalence community, the total cost of expanding MMT by 10% was $17,000,000 (discounted at 3%) over 10 years. After reductions in HIV care costs were considered, the incremental cost of this programme was $10,900,000 (discounted). For the low prevalence community, the total cost of expanding MMT by 10% was $4,800,000 (discounted at 3%) over 10 years. After reductions in HIV care costs were considered, the incremental cost of this programme was $3,300,000 (discounted).
Synthesis of costs and benefits
Results are reported as the cost per QALY gained. In the high prevalence community, base rate values suggested that the cost per QALY gained was $8,200 whilst in the low prevalence community, the cost was $10,900 per QALY gained. Table 2 in the paper shows how modified quality of life, cost and effectiveness assumptions affect these results. These results were reasonably sensitive to the cost of methadone maintenance, the fraction of injection drug users leaving MMT who quit drug use, the fraction of injections that were shared and non-HIV related health care costs.
The model's results were fairly robust to such parameters as condom use among drug users, reduction in the number of sexual partners for drug users in MMT, the magnitude of the expansion of MMT and the discount rate.
